S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Biden To Unleash "Choke Point" Operation On America? (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Biden To Unleash "Choke Point" Operation On America? (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Biden To Unleash "Choke Point" Operation On America? (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Biden To Unleash "Choke Point" Operation On America? (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Biden To Unleash "Choke Point" Operation On America? (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.32
+0.06 (+2.65%)
(As of 03/24/2023 08:51 PM ET)
Add
Compare
Today's Range
$2.19
$2.34
50-Day Range
$2.17
$2.68
52-Week Range
$1.31
$3.48
Volume
372,900 shs
Average Volume
406,353 shs
Market Capitalization
$437.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
374.1% Upside
$11.00 Price Target
Short Interest
Healthy
2.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

569th out of 995 stocks

Pharmaceutical Preparations Industry

270th out of 482 stocks


LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
11/03/2021
Today
3/26/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+180.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-101,940,000.00
Net Margins
-73,341.00%
Pretax Margin
-73,341.01%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$0.62 per share

Miscellaneous

Free Float
176,459,000
Market Cap
$437.85 million
Optionable
Optionable
Beta
1.32

Social Links


Key Executives

  • Lonnel Coats
    Chief Executive Officer & Director
  • Jeffrey L. Wade
    President & Chief Financial Officer
  • Craig B. Granowitz
    Chief Medical Officer & Senior Vice President
  • Brian T. Crum
    Secretary, Senior Vice President & General Counsel
  • Kiernan A. Seth
    Chief Commercial Officer & Vice President













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

3 brokers have issued twelve-month price objectives for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $20.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 374.1% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2023?

Lexicon Pharmaceuticals' stock was trading at $1.91 on January 1st, 2023. Since then, LXRX stock has increased by 21.5% and is now trading at $2.32.
View the best growth stocks for 2023 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 96.02% and a negative net margin of 73,341.00%. During the same period last year, the business earned $0.71 EPS.

What ETFs hold Lexicon Pharmaceuticals' stock?

ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.05%), Pinnacle Associates Ltd. (1.02%), Geode Capital Management LLC (0.85%), Point72 Asset Management L.P. (0.71%) and Millennium Management LLC (0.62%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.32.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $437.85 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 3/27/2023 by MarketBeat.com Staff